Human Genome Sciences
Part of GSK
CompanyUnited StatesFounded 1992
Human Genome Sciences develops 2 assets, the furthest approved (Benlysta in lupus nephritis). Mostly antibody acting on TNFSF13B and PRDX1; based in the United States, founded in 1992.
- 2
- Assets
- Furthest stage
- Approved
- 27
- Trials
- 7
- Signals
Pipeline
2Approved, Antibody, TNFSF13B, lupus nephritis, Lupus Erythematosus, Systemic
Binds anthrax protective antigen, blocking toxin entry into host cells.
Approved, Antibody, PRDX1, Anthrax, bacterial infection (Phase 3)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials35
- Signals7
- Similar companies6